Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -31.22% | 46.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.74% | 26.39% | |||
| Operating Income | 58.74% | -455.58% | |||
| Income Before Tax | 62.61% | -432.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 62.61% | -282.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.61% | -282.07% | |||
| EBIT | 58.74% | -455.58% | |||
| EBITDA | 58.73% | -455.27% | |||
| EPS Basic | 62.63% | -254.22% | |||
| Normalized Basic EPS | 59.89% | -381.65% | |||
| EPS Diluted | 61.91% | -255.59% | |||
| Normalized Diluted EPS | 59.89% | -388.46% | |||
| Average Basic Shares Outstanding | 0.01% | 18.09% | |||
| Average Diluted Shares Outstanding | 0.01% | 15.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
